---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-21-033010"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2021-09-30T23:59:59+00:00"
generated_at: "2026-06-29T00:27:09.151649+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cyclerion updates three CY6463 trials: CIAS Phase 1b enrolled, MELAS topline H1 2022, ADv screening

## Summary
- First patients enrolled in Phase 1b study of CY6463 for cognitive impairment associated with schizophrenia (CIAS).
- Phase 2a in MELAS remains enrolling; topline clinical results now expected in H1 2022.
- Patient screening started in Phase 2a study of CY6463 for Alzheimer's disease with vascular pathology (ADv).

## SEC filing metadata
- accession: 0001140361-21-033010
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2021-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000114036121033010/0001140361-21-033010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000114036121033010/brhc10029438_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-21-033010
- JSON: https://secwatch.observer/filing/0001140361-21-033010.json
- Plain text: https://secwatch.observer/filing/0001140361-21-033010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.